Form 4: Kezar Life Sciences CFO Acquires Stock Options Following Performance Milestone

Marc Belsky, CFO of Kezar Life Sciences, gains rights to purchase 7,200 shares of common stock following achievement of performance criteria.

Summary

• On July 11, 2024, Marc Belsky, the CFO of Kezar Life Sciences, was granted an option to purchase 12,000 shares of common stock.
• The options vest on July 11, 2025, contingent upon achieving non-financial performance criteria and continued service.
• On March 4, 2025, the company's Compensation Committee certified that performance criteria were met for 7,200 shares.
• As a result, Belsky will have the right to purchase 7,200 shares on July 11, 2025, if he remains employed by the company.
• The exercise price of the options is $6.30 per share, and they expire on July 10, 2034.
• Following this transaction, Belsky beneficially owns 7,200 derivative securities (employee stock options).

Sentiment

Score: 7

Explanation: The document indicates achievement of performance criteria, which is a positive sign. The vesting of stock options incentivizes the CFO, aligning his interests with the company's success. However, it's a standard executive compensation practice, so the sentiment is moderately positive.

Positives

• The vesting of stock options for the CFO indicates that the company has achieved certain non-financial performance goals.
• The CFO's continued service is incentivized through the vesting requirements.

Risks

• The vesting of the options is contingent on the CFO's continued employment with the company.

Future Outlook

The CFO will be able to exercise the options to purchase 7,200 shares of common stock on July 11, 2025, if he continues to be employed by the company.

Management Comments

• The Company's Compensation Committee certified that certain of the non-financial performance criteria were achieved for 7,200 shares underlying the option.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for executives in biotech companies like Kezar Life Sciences.
• The vesting schedules and performance criteria are generally aligned with industry practices to incentivize long-term value creation.
• Comparable companies such as Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• Shareholders may view the achievement of performance criteria positively.
• Employees may be motivated by the company's success in meeting its goals.
• The CFO is incentivized to continue contributing to the company's success.

Next Steps

• The CFO will need to continue providing service to the company through July 11, 2025, for the options to vest.
• The CFO may exercise the options after the vesting date.

Key Dates